A Real World Experience of Dapagliflozin in Type 2 Diabetes
Dapaglifozin in Type 2 Diabetes Mellitus Patients: A Single-centre Retrospective Cohort Study
調査の概要
状態
条件
詳細な説明
The prevalence of type 2 diabetes among adults >18 years old is 17.5% in Malaysia, where half of them are undiagnosed. Diabetes also accounts for 14.5% of all-cause mortality worldwide, with close to half of the deaths are in subjects <60 years old. These highlight the importance of early diagnosis of disease, timely intervention with appropriate therapy, and treating type 2 diabetes patients to goal to prevent the development of complications.
Asian type 2 diabetes phenotypes are different than Caucasians, i.e. significant pancreatic beta-cell dysfunction, higher visceral adiposity, more vulnerable to cardio-renal complications. Although clinical trials of SGLT-2 inhibitors have been published, real-world data on the use of this new class of antidiabetic medication is still lacking, in particularly among Asians.
研究の種類
入学 (実際)
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
All adult T2DM patients who received at least one prescription for dapagliflozin for the first time between March 2014 and December 2015 at the University of Malaya Medical Center (UMMC) will be recruited. UMMC is an academic medical institution with 1,300 beds, serving a population of 1.8 million in Kuala Lumpur, Malaysia.
The date of the first prescription for dapagliflozin in the Hospital Pharmacy Database is defined as the index date. Dapaglifozin is only available at the study site from March 2014 onwards.
説明
Inclusion Criteria:
- Diagnosis of T2DM prior to the first prescription of dapagliflozin
- Patients with T2DM who are initiated with dapagliflozin from March 2014 till December 2015
- Patients need to be on dapagliflozin therapy for at least six consecutive months from the index date
- Patients need to have diabetologists/endocrinologists' follow up for at least six months after the initiation of dapagliflozin
Exclusion Criteria:
- Patients with T2DM who are initiated with dapagliflozin after December 2015
- Patients with incomplete electronic medical records
- Patients with Type 1 diabetes
- Patients with latent autoimmune diabetes of adults (LADA)
- Female Patients with T2DM who are found to be pregnant during the treatment period of dapagliflozin
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:ケースのみ
- 時間の展望:回顧
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Change in HbA1c
時間枠:6 months
|
To assess the change in HbA1c from baseline to 6 months
|
6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Change in body weight
時間枠:6 months
|
To assess the change in body weight from baseline to 6 months
|
6 months
|
Change in estimated glomerular filtration rate
時間枠:6 months
|
To assess the change in estimates glomerular filtration rate from baseline to 6 months
|
6 months
|
Change in albuminuria
時間枠:6 months
|
To assess the change in albuminuria from baseline to 6 months
|
6 months
|
Change in body mass index
時間枠:6 months
|
To assess the change in body mass index from baseline to 6 months
|
6 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Lee Ling LIM, MRCP (UK)、University of Malaya, Malaysia
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
2型糖尿病の臨床試験
-
National Human Genome Research Institute (NHGRI)完了